RESEARCHER PROFILE
Scott J. Rodig
S
Harvard University
Scott J. Rodig works in Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lymphoma Diagnosis and Treatment, Cancer Genomics and Diagnostics. Recorded institutional associations include Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute.
1,578Publications
78,060Citations
130H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 · 3,560 citationsAn immunogenic personal neoantigen vaccine for patients with melanoma
2017 · 2,917 citationsComprehensive analyses of tumor immunity: implications for cancer immunotherapy
2016 · 2,451 citationsSubsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
2019 · 2,063 citationsMolecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
2018 · 1,935 citationsClinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
2009 · 1,870 citationsTargeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway
1996 · 1,657 citationsAdaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
2016 · 1,577 citationsAdaptive immunity maintains occult cancer in an equilibrium state
2007 · 1,436 citationsNeoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
2018 · 1,425 citationsIntegrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
2010 · 1,305 citationsMYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
2012 · 1,294 citationsActivation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
2013 · 1,231 citationsNivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
2016 · 1,001 citationsIbrutinib in Previously Treated Waldenström’s Macroglobulinemia
2015 · 942 citationsNivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
2016 · 927 citationsCrizotinib in ALK -Rearranged Inflammatory Myofibroblastic Tumor
2010 · 870 citationsCooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
2019 · 869 citationsDisruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses
1998 · 853 citationsPD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
2013 · 843 citationsPD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
2016 · 791 citationsTet1 and Tet2 Regulate 5-Hydroxymethylcytosine Production and Cell Lineage Specification in Mouse Embryonic Stem Cells
2011 · 775 citationsDiscovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
2013 · 733 citationsConstitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
2012 · 685 citationsAssociation of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
2015 · 684 citations
